Recent advances in chronic granulomatous disease

J Infect. 2014 Nov:69 Suppl 1:S32-5. doi: 10.1016/j.jinf.2014.07.013. Epub 2014 Sep 26.

Abstract

Chronic Granulomatous Disease (CGD) is a primary immunodeficiency caused by abnormities in the NADPH Oxidase that is involved in the respiratory burst responsible for initiating the killing of microbes ingested by phagocytic cells. The hallmark of CGD is recurrent infection but the inflammatory complications can prove difficult to treat. New insights into the mechanisms responsible for the inflammatory complications have led to new therapies. The treatment of CGD colitis with an anti-tumour necrosis alpha agent has been shown to be successful but associated with significant infectious complications. Haematopoietic stem cell transplants offer the possibility of cure for those with ether a matched or unrelated donor transplant, with results of the latter improving significantly over recent years. Gene Therapy offers the promise of cure without the need for a transplant but better vectors are required.

Keywords: Gene therapy; Haematopoietic stem cell transplant; Immunocompromise; Primary immunodeficiency.

Publication types

  • Review

MeSH terms

  • Genetic Therapy
  • Granulomatous Disease, Chronic / diagnosis*
  • Granulomatous Disease, Chronic / etiology
  • Granulomatous Disease, Chronic / therapy*
  • Hematopoietic Stem Cell Transplantation
  • Humans